Polynucleotides and polypeptide sequences involved in cancer

Abstract

The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.

1 - 126 . (canceled) 
     
     
         127 . A method of treating cancer, the method comprising selecting a cancer patient having a tumor comprising cells expressing Kidney Associated Antigen 1 (KAAG1) and administering an antibody or an antigen binding fragment thereof that specifically binds to SEQ ID NO.:70 to the cancer patient. 
     
     
         128 . The method of  claim 127 , wherein the antibody or antigen binding fragment thereof is linked to a toxin. 
     
     
         129 . The method of  claim 127 , wherein the cancer is ovarian cancer. 
     
     
         130 . The method of  claim 128 , wherein the cancer is ovarian cancer. 
     
     
         131 . The method of  claim 129 , wherein the ovarian cancer is late stage ovarian cancer. 
     
     
         132 . The method of  claim 130 , wherein the ovarian cancer is late stage ovarian cancer. 
     
     
         133 . The method of  claim 127 , wherein the selection step is performed by assessing the presence of KAAG1 mRNA or KAAG1 protein in the tumor. 
     
     
         134 . The method of  claim 127 , wherein the cancer patient is treated by chemotherapy. 
     
     
         135 . The method of  claim 127 , wherein the cancer patient has a level of CA-125 higher than normal. 
     
     
         136 . A method of treating cancer, the method comprising administering an antibody or an antigen binding fragment thereof that specifically binds to SEQ ID NO.:70 to a cancer patient, wherein the antibody or antigen binding fragment thereof is linked to a toxin. 
     
     
         137 . The method of  claim 136 , wherein the cancer patient suffers from ovarian cancer. 
     
     
         138 . The method of  claim 136 , wherein the cancer patient suffers from late stage ovarian cancer. 
     
     
         139 . The method of  claim 136 , wherein the cancer patient has a level of CA-125 higher than normal. 
     
     
         140 . The method of  claim 136 , wherein the cancer patient is treated with a chemotherapeutic agent.